Causal relationship between immune cells and the risk of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis: A Mendelian randomization study

被引:0
|
作者
Cai, Xiaojing [1 ]
Li, Junhua [1 ]
Wu, Manyi [1 ]
Liu, Qingquan [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Nephrol, Wuhan, Peoples R China
来源
FASEB JOURNAL | 2024年 / 38卷 / 14期
关键词
ANCA; causal inference; genome-wide association study; immunity; myeloperoxidase; randomization analysis; REGULATORY T-CELLS; EOSINOPHILIC GRANULOMATOSIS; CD8(+) CD28(-); B-CELLS; SERUM; CD8(+)CD28(-); LYMPHOCYTES; EXPRESSION; REMISSION; INCREASES;
D O I
10.1096/fj.202400141R
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disease categorized as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The majority of patients are ANCA-positive, predominantly against myeloperoxidase (MPO). Previous studies have predominantly concentrated on the association between EGPA and neutrophils, but recent research has emphasized the role of lymphocytes in the development of EGPA. The objective of our research was to examine the causal association between immune cells and MPO + ANCA EGPA. A two-sample bidirectional Mendelian randomization (MR) analysis was performed, which included 159 MPO + ANCA EGPA cases and 6688 controls and utilized Genome-Wind Associaton Studies (GWAS) summary statistics of immune traits from approximately 3757 individuals, encompassing around 22 million single nucleotide polymorphisms (SNPs). Our findings revealed that 23 immunophenotypes were associated with MPO + ANCA EGPA. Furthermore, the reverse MR analysis showed that MPO + ANCA EGPA had significant causal effects on three immunophenotypes within the Treg panel. By integrating existing research, our study unveiled the contributions of Tregs, B cells, and monocytes to the development of EGPA. Subgroup analysis specifically examined the roles of lymphocyte subtypes, cytokines, and their surface molecules in the pathogenic mechanisms of the disease. This comprehensive approach provides a novel perspective on the biological mechanisms and early intervention strategies for MPO + ANCA EGPA by focusing on immune cells.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Clinical Characteristics of Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Caused by Antithyroid Drugs
    Noh, Jaeduk Yoshimura
    Yasuda, Shigemitu
    Sato, Shotaro
    Matsumoto, Masako
    Kunii, Yo
    Noguchi, Yoshihiko
    Mukasa, Koji
    Ito, Kunihiko
    Ito, Koichi
    Sugiyama, Osamu
    Kobayashi, Hiroshi
    Nihojima, Shigeru
    Okazaki, Masaru
    Yokoyama, Shunji
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (08): : 2806 - 2811
  • [22] Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis: Report of five cases
    Hasegawa, M
    Kawamura, N
    Kasugai, M
    Koide, S
    Murase, M
    Asano, S
    Toba, T
    Kushimoto, H
    Murakami, K
    Tomita, M
    Shikano, M
    Sugiyama, S
    THERAPEUTIC APHERESIS, 2002, 6 (06): : 443 - 449
  • [23] Acute Coronary Syndrome Due to Myeloperoxidase-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Nakase, Masaaki
    Yahagi, Kazuyuki
    Oshima, Asahi
    Kikushima, Hosei
    Ninomiya, Kai
    Tanaka, Tetsu
    Horiuchi, Yu
    Asami, Masahiko
    Yuzawa, Hitomi
    Komiyama, Kota
    Tanaka, Jun
    Aoki, Jiro
    Suzuki, Akitake
    Tanabe, Kengo
    JACC-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (23) : E215 - E216
  • [24] Vanishing Immunoglobulins: The Formation of Pauci-Immune Lesions in Myeloperoxidase-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Futamata, Emika
    Masuda, Sakiko
    Nishibata, Yuka
    Tanaka, Satoshi
    Tomaru, Utano
    Ishizu, Akihiro
    NEPHRON, 2018, 138 (04) : 328 - 330
  • [25] An update on risk factors for relapse in antineutrophil cytoplasmic antibody-associated vasculitis
    Zhou, Han
    Liang, Wei
    Hu, Hongtu
    Liu, Zikang
    Chu, Fan
    Ding, Guohua
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2024, 218 (02): : 120 - 135
  • [26] Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis
    Gaskin, G
    Pusey, CD
    THERAPEUTIC APHERESIS, 2001, 5 (03): : 176 - 181
  • [27] Otolaryngologic Manifestations of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Nakamaru, Yuji
    Takagi, Dai
    Oridate, Nobuhiko
    Homma, Akihiro
    Fukuda, Satoshi
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2012, 146 (01) : 119 - 121
  • [28] The Expanding Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Armamentarium
    Mcgovern, Dominic P.
    Jones, Rachel B.
    Jayne, David R. W.
    Smith, Rona M.
    DRUGS, 2025,
  • [29] Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Prendecki, Maria
    Gulati, Kavita
    Pisacano, Noelle
    Pinheiro, Damilola
    Bhatt, Tejal
    Mawhin, Marie-Anne
    Toulza, Frederic
    Masuda, Esteban S.
    Cowburn, Andrew
    Lodge, Katharine M.
    Tam, Frederick W. K.
    Roufosse, Candice
    Pusey, Charles D.
    McAdoo, Stephen P.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 (01) : 84 - 97
  • [30] Association Between Reappearance of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Subgroup Analysis of Nationwide Prospective Cohort Studies
    Watanabe, Haruki
    Sada, Ken-Ei
    Matsumoto, Yoshinori
    Harigai, Masayoshi
    Amano, Koichi
    Dobashi, Hiroaki
    Fujimoto, Shouichi
    Usui, Joichi
    Yamagata, Kunihiro
    Atsumi, Tatsuya
    Banno, Shogo
    Sugihara, Takahiko
    Arimura, Yoshihiro
    Matsuo, Seiichi
    Makino, Hirofumi
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (10) : 1626 - 1633